Nektar Therapeutics Aktie
WKN: 165417 / ISIN: US6402681083
01.07.2022 12:45:32
|
Nektar Therapeutics Promotes Chief Accounting Officer Jillian Thomsen To CFO
(RTTNews) - Nektar Therapeutics (NKTR) announced Friday the promotion of Jillian Thomsen to Senior Vice President (SVP) & Chief Financial Officer. Thomsen has served as SVP, Finance & Chief Accounting Officer of Nektar since 2008, and is a key member of the Executive Committee.
Gil Labrucherie, the company's current Chief Operating Officer & Chief Financial Officer, will be departing the company to pursue another opportunity at a private biotechnology company.
In April 2008, Thomsen was appointed Chief Accounting Officer at Nektar and joined the Executive Committee. She has over 30 years of finance and accounting experience.
In her current role, Thomsen oversees accounting, financial reporting, FP&A, Sarbanes-Oxley compliance, treasury, tax, clinical outsourcing, and procurement functions at the company. From 2006 to 2008, she served as Vice President, Finance and Controller of Nektar.
Prior to joining Nektar in 2006, Thomsen was Deputy Controller of Calpine Corp. from September 2002 to February 2006.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Nektar Therapeuticsmehr Nachrichten
20:05 |
NASDAQ Composite aktuell: NASDAQ Composite notiert am Nachmittag im Plus (finanzen.at) | |
18:02 |
Börse New York in Grün: NASDAQ Composite am Mittag mit Zuschlägen (finanzen.at) | |
16:04 |
NASDAQ Composite Index-Wert Nektar Therapeutics-Aktie: So viel hätte eine Investition in Nektar Therapeutics von vor einem Jahr gekostet (finanzen.at) | |
18.04.25 |
NASDAQ Composite Index-Titel Nektar Therapeutics-Aktie: So viel Verlust wäre bei einem Investment in Nektar Therapeutics von vor 10 Jahren angefallen (finanzen.at) | |
17.04.25 |
NASDAQ-Handel: NASDAQ Composite beginnt Donnerstagshandel in der Gewinnzone (finanzen.at) | |
16.04.25 |
Börse New York: NASDAQ Composite präsentiert sich leichter (finanzen.at) | |
15.04.25 |
Zurückhaltung in New York: NASDAQ Composite verliert letztendlich (finanzen.at) | |
15.04.25 |
Freundlicher Handel in New York: So performt der NASDAQ Composite am Mittag (finanzen.at) |
Analysen zu Nektar Therapeuticsmehr Analysen
Aktien in diesem Artikel
Nektar Therapeutics | 0,66 | 2,79% |
|